Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
Summary Background and Aims Liver involvement is an increasingly recognised complication of common variable immunodeficiency (CVID). Nodular regenerative hyperplasia (NRH), a subgroup of porto‐sinusoidal vascular disorder, and manifestations of portal hypertension (PH) unrelated to cirrhosis are the...
Gespeichert in:
Veröffentlicht in: | Alimentary pharmacology & therapeutics 2024-10, Vol.60 (7), p.888-896 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 896 |
---|---|
container_issue | 7 |
container_start_page | 888 |
container_title | Alimentary pharmacology & therapeutics |
container_volume | 60 |
creator | Hercun, Julian Asif, Bilal Vittal, Anusha Ahmed, Abdel Gopalakrishna Pillai, Harish Kumar Bergerson, Jenna R. E. Holland, Steven Uzel, Gulbu Strober, Warren Fuss, Ivan J. Koh, Christopher Kleiner, David E. Heller, Theo |
description | Summary
Background and Aims
Liver involvement is an increasingly recognised complication of common variable immunodeficiency (CVID). Nodular regenerative hyperplasia (NRH), a subgroup of porto‐sinusoidal vascular disorder, and manifestations of portal hypertension (PH) unrelated to cirrhosis are the most common findings. Nonetheless, the evolution of liver disease over time remains unknown.
Methods
Retrospective review of patients followed at the National Institutes of Health with CVID‐related liver disease and liver biopsy from 1990 to 2020. Clinical, imaging and histological follow‐up were recorded as part of clinical research protocols.
Results
Forty patients were included, with a median age of 37.5 years at initial biopsy, 73% presenting with clear evidence of NRH, and a median fibrosis stage of 1. At biopsy, median platelet count was 100 × 109/L, spleen size 19.5 cm, hepatic venous pressure gradient 9.5 mmHg and 37.5% of patients had signs of PH. Cumulative incidence of PH was 65% at 5 years. In a subgroup of 16 patients, a follow‐up liver biopsy, performed at a median time of 3 years after the index biopsy, revealed an increase in fibrosis by ≥2 stages in 31% of cases and an increase to an overall stage of 2.2 (p = 0.001). No clinical or histological factors were associated with progression of fibrosis.
Conclusions
In this CVID cohort, NRH is the most common initial histological finding; however, unexpectedly fibrosis progresses over time in a subgroup of patients. A better understanding of the underlying causal process of liver disease CVID might lead to improved outcomes. |
doi_str_mv | 10.1111/apt.18180 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3087355223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3122086393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3130-94cfcfd381be47508b07380afd3ee0e89af5f856bc22e47f5251d647ddece4343</originalsourceid><addsrcrecordid>eNp10c9OHSEUBnDS2NRb20VfwJC4aRejB5g_zNJYrSYm7cKuCQOHFMMMI8xo7q6P4DP6JMVe20WTsiGQH1_I-Qj5wOCYlXWi5-WYSSbhFdkw0TYVB9HukQ3wtq-4ZGKfvM35FgDaDvgbsi966EHWYkPSZ7zHEOcRp4VGR3_grBdvqPNDitln6idq4jjGid7r5PUQkPpxXKdo0XnjcTLbp5-PCYNe0NI5piWWc_bTmqO3OpRn2axBJ2p9jsliekdeOx0yvn_ZD8j3i_Obs8vq-uuXq7PT68oIJqDqa-OMs0KyAeuuATlAJyTocoUIKHvtGiebdjCcF-Aa3jDb1p21aLAWtTggH3e5c4p3K-ZFjT4bDEFPGNesBMhONA3notCjf-htXNNUfqcE4xxkK_pn9WmnTBlNTujUnPyo01YxUM9FqFKE-l1EsYcvieswov0r_0y-gJMdePABt_9PUqffbnaRvwDqtZZq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3122086393</pqid></control><display><type>article</type><title>Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hercun, Julian ; Asif, Bilal ; Vittal, Anusha ; Ahmed, Abdel ; Gopalakrishna Pillai, Harish Kumar ; Bergerson, Jenna R. E. ; Holland, Steven ; Uzel, Gulbu ; Strober, Warren ; Fuss, Ivan J. ; Koh, Christopher ; Kleiner, David E. ; Heller, Theo</creator><creatorcontrib>Hercun, Julian ; Asif, Bilal ; Vittal, Anusha ; Ahmed, Abdel ; Gopalakrishna Pillai, Harish Kumar ; Bergerson, Jenna R. E. ; Holland, Steven ; Uzel, Gulbu ; Strober, Warren ; Fuss, Ivan J. ; Koh, Christopher ; Kleiner, David E. ; Heller, Theo</creatorcontrib><description>Summary
Background and Aims
Liver involvement is an increasingly recognised complication of common variable immunodeficiency (CVID). Nodular regenerative hyperplasia (NRH), a subgroup of porto‐sinusoidal vascular disorder, and manifestations of portal hypertension (PH) unrelated to cirrhosis are the most common findings. Nonetheless, the evolution of liver disease over time remains unknown.
Methods
Retrospective review of patients followed at the National Institutes of Health with CVID‐related liver disease and liver biopsy from 1990 to 2020. Clinical, imaging and histological follow‐up were recorded as part of clinical research protocols.
Results
Forty patients were included, with a median age of 37.5 years at initial biopsy, 73% presenting with clear evidence of NRH, and a median fibrosis stage of 1. At biopsy, median platelet count was 100 × 109/L, spleen size 19.5 cm, hepatic venous pressure gradient 9.5 mmHg and 37.5% of patients had signs of PH. Cumulative incidence of PH was 65% at 5 years. In a subgroup of 16 patients, a follow‐up liver biopsy, performed at a median time of 3 years after the index biopsy, revealed an increase in fibrosis by ≥2 stages in 31% of cases and an increase to an overall stage of 2.2 (p = 0.001). No clinical or histological factors were associated with progression of fibrosis.
Conclusions
In this CVID cohort, NRH is the most common initial histological finding; however, unexpectedly fibrosis progresses over time in a subgroup of patients. A better understanding of the underlying causal process of liver disease CVID might lead to improved outcomes.</description><identifier>ISSN: 0269-2813</identifier><identifier>ISSN: 1365-2036</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.18180</identifier><identifier>PMID: 39090843</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Biopsy ; Cirrhosis ; Common variable immunodeficiency ; Fibrosis ; Hyperplasia ; Immune system ; Liver diseases ; Vein & artery diseases</subject><ispartof>Alimentary pharmacology & therapeutics, 2024-10, Vol.60 (7), p.888-896</ispartof><rights>Published 2024. This article is a U.S. Government work and is in the public domain in the USA.</rights><rights>Copyright © 2024 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3130-94cfcfd381be47508b07380afd3ee0e89af5f856bc22e47f5251d647ddece4343</cites><orcidid>0000-0001-7608-0914 ; 0000-0002-3855-5023 ; 0000-0002-4755-5607</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.18180$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.18180$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39090843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hercun, Julian</creatorcontrib><creatorcontrib>Asif, Bilal</creatorcontrib><creatorcontrib>Vittal, Anusha</creatorcontrib><creatorcontrib>Ahmed, Abdel</creatorcontrib><creatorcontrib>Gopalakrishna Pillai, Harish Kumar</creatorcontrib><creatorcontrib>Bergerson, Jenna R. E.</creatorcontrib><creatorcontrib>Holland, Steven</creatorcontrib><creatorcontrib>Uzel, Gulbu</creatorcontrib><creatorcontrib>Strober, Warren</creatorcontrib><creatorcontrib>Fuss, Ivan J.</creatorcontrib><creatorcontrib>Koh, Christopher</creatorcontrib><creatorcontrib>Kleiner, David E.</creatorcontrib><creatorcontrib>Heller, Theo</creatorcontrib><title>Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background and Aims
Liver involvement is an increasingly recognised complication of common variable immunodeficiency (CVID). Nodular regenerative hyperplasia (NRH), a subgroup of porto‐sinusoidal vascular disorder, and manifestations of portal hypertension (PH) unrelated to cirrhosis are the most common findings. Nonetheless, the evolution of liver disease over time remains unknown.
Methods
Retrospective review of patients followed at the National Institutes of Health with CVID‐related liver disease and liver biopsy from 1990 to 2020. Clinical, imaging and histological follow‐up were recorded as part of clinical research protocols.
Results
Forty patients were included, with a median age of 37.5 years at initial biopsy, 73% presenting with clear evidence of NRH, and a median fibrosis stage of 1. At biopsy, median platelet count was 100 × 109/L, spleen size 19.5 cm, hepatic venous pressure gradient 9.5 mmHg and 37.5% of patients had signs of PH. Cumulative incidence of PH was 65% at 5 years. In a subgroup of 16 patients, a follow‐up liver biopsy, performed at a median time of 3 years after the index biopsy, revealed an increase in fibrosis by ≥2 stages in 31% of cases and an increase to an overall stage of 2.2 (p = 0.001). No clinical or histological factors were associated with progression of fibrosis.
Conclusions
In this CVID cohort, NRH is the most common initial histological finding; however, unexpectedly fibrosis progresses over time in a subgroup of patients. A better understanding of the underlying causal process of liver disease CVID might lead to improved outcomes.</description><subject>Biopsy</subject><subject>Cirrhosis</subject><subject>Common variable immunodeficiency</subject><subject>Fibrosis</subject><subject>Hyperplasia</subject><subject>Immune system</subject><subject>Liver diseases</subject><subject>Vein & artery diseases</subject><issn>0269-2813</issn><issn>1365-2036</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp10c9OHSEUBnDS2NRb20VfwJC4aRejB5g_zNJYrSYm7cKuCQOHFMMMI8xo7q6P4DP6JMVe20WTsiGQH1_I-Qj5wOCYlXWi5-WYSSbhFdkw0TYVB9HukQ3wtq-4ZGKfvM35FgDaDvgbsi966EHWYkPSZ7zHEOcRp4VGR3_grBdvqPNDitln6idq4jjGid7r5PUQkPpxXKdo0XnjcTLbp5-PCYNe0NI5piWWc_bTmqO3OpRn2axBJ2p9jsliekdeOx0yvn_ZD8j3i_Obs8vq-uuXq7PT68oIJqDqa-OMs0KyAeuuATlAJyTocoUIKHvtGiebdjCcF-Aa3jDb1p21aLAWtTggH3e5c4p3K-ZFjT4bDEFPGNesBMhONA3notCjf-htXNNUfqcE4xxkK_pn9WmnTBlNTujUnPyo01YxUM9FqFKE-l1EsYcvieswov0r_0y-gJMdePABt_9PUqffbnaRvwDqtZZq</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Hercun, Julian</creator><creator>Asif, Bilal</creator><creator>Vittal, Anusha</creator><creator>Ahmed, Abdel</creator><creator>Gopalakrishna Pillai, Harish Kumar</creator><creator>Bergerson, Jenna R. E.</creator><creator>Holland, Steven</creator><creator>Uzel, Gulbu</creator><creator>Strober, Warren</creator><creator>Fuss, Ivan J.</creator><creator>Koh, Christopher</creator><creator>Kleiner, David E.</creator><creator>Heller, Theo</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7608-0914</orcidid><orcidid>https://orcid.org/0000-0002-3855-5023</orcidid><orcidid>https://orcid.org/0000-0002-4755-5607</orcidid></search><sort><creationdate>202410</creationdate><title>Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder</title><author>Hercun, Julian ; Asif, Bilal ; Vittal, Anusha ; Ahmed, Abdel ; Gopalakrishna Pillai, Harish Kumar ; Bergerson, Jenna R. E. ; Holland, Steven ; Uzel, Gulbu ; Strober, Warren ; Fuss, Ivan J. ; Koh, Christopher ; Kleiner, David E. ; Heller, Theo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3130-94cfcfd381be47508b07380afd3ee0e89af5f856bc22e47f5251d647ddece4343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biopsy</topic><topic>Cirrhosis</topic><topic>Common variable immunodeficiency</topic><topic>Fibrosis</topic><topic>Hyperplasia</topic><topic>Immune system</topic><topic>Liver diseases</topic><topic>Vein & artery diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hercun, Julian</creatorcontrib><creatorcontrib>Asif, Bilal</creatorcontrib><creatorcontrib>Vittal, Anusha</creatorcontrib><creatorcontrib>Ahmed, Abdel</creatorcontrib><creatorcontrib>Gopalakrishna Pillai, Harish Kumar</creatorcontrib><creatorcontrib>Bergerson, Jenna R. E.</creatorcontrib><creatorcontrib>Holland, Steven</creatorcontrib><creatorcontrib>Uzel, Gulbu</creatorcontrib><creatorcontrib>Strober, Warren</creatorcontrib><creatorcontrib>Fuss, Ivan J.</creatorcontrib><creatorcontrib>Koh, Christopher</creatorcontrib><creatorcontrib>Kleiner, David E.</creatorcontrib><creatorcontrib>Heller, Theo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hercun, Julian</au><au>Asif, Bilal</au><au>Vittal, Anusha</au><au>Ahmed, Abdel</au><au>Gopalakrishna Pillai, Harish Kumar</au><au>Bergerson, Jenna R. E.</au><au>Holland, Steven</au><au>Uzel, Gulbu</au><au>Strober, Warren</au><au>Fuss, Ivan J.</au><au>Koh, Christopher</au><au>Kleiner, David E.</au><au>Heller, Theo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2024-10</date><risdate>2024</risdate><volume>60</volume><issue>7</issue><spage>888</spage><epage>896</epage><pages>888-896</pages><issn>0269-2813</issn><issn>1365-2036</issn><eissn>1365-2036</eissn><abstract>Summary
Background and Aims
Liver involvement is an increasingly recognised complication of common variable immunodeficiency (CVID). Nodular regenerative hyperplasia (NRH), a subgroup of porto‐sinusoidal vascular disorder, and manifestations of portal hypertension (PH) unrelated to cirrhosis are the most common findings. Nonetheless, the evolution of liver disease over time remains unknown.
Methods
Retrospective review of patients followed at the National Institutes of Health with CVID‐related liver disease and liver biopsy from 1990 to 2020. Clinical, imaging and histological follow‐up were recorded as part of clinical research protocols.
Results
Forty patients were included, with a median age of 37.5 years at initial biopsy, 73% presenting with clear evidence of NRH, and a median fibrosis stage of 1. At biopsy, median platelet count was 100 × 109/L, spleen size 19.5 cm, hepatic venous pressure gradient 9.5 mmHg and 37.5% of patients had signs of PH. Cumulative incidence of PH was 65% at 5 years. In a subgroup of 16 patients, a follow‐up liver biopsy, performed at a median time of 3 years after the index biopsy, revealed an increase in fibrosis by ≥2 stages in 31% of cases and an increase to an overall stage of 2.2 (p = 0.001). No clinical or histological factors were associated with progression of fibrosis.
Conclusions
In this CVID cohort, NRH is the most common initial histological finding; however, unexpectedly fibrosis progresses over time in a subgroup of patients. A better understanding of the underlying causal process of liver disease CVID might lead to improved outcomes.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39090843</pmid><doi>10.1111/apt.18180</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7608-0914</orcidid><orcidid>https://orcid.org/0000-0002-3855-5023</orcidid><orcidid>https://orcid.org/0000-0002-4755-5607</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-2813 |
ispartof | Alimentary pharmacology & therapeutics, 2024-10, Vol.60 (7), p.888-896 |
issn | 0269-2813 1365-2036 1365-2036 |
language | eng |
recordid | cdi_proquest_miscellaneous_3087355223 |
source | Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Biopsy Cirrhosis Common variable immunodeficiency Fibrosis Hyperplasia Immune system Liver diseases Vein & artery diseases |
title | Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T02%3A13%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20hepatic%20fibrosis%20in%20common%20variable%20immunodeficiency%E2%80%90related%20porto%E2%80%90sinusoidal%20vascular%20disorder&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Hercun,%20Julian&rft.date=2024-10&rft.volume=60&rft.issue=7&rft.spage=888&rft.epage=896&rft.pages=888-896&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.18180&rft_dat=%3Cproquest_cross%3E3122086393%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3122086393&rft_id=info:pmid/39090843&rfr_iscdi=true |